-
公开(公告)号:US08952056B2
公开(公告)日:2015-02-10
申请号:US12919012
申请日:2009-02-23
申请人: Michael Eissenstat , Dehui Duan , Sergi Gulnik , John W. Erickson
发明人: Michael Eissenstat , Dehui Duan , Sergi Gulnik , John W. Erickson
IPC分类号: A61K31/343 , C07D307/78 , C07D307/79
CPC分类号: C07D307/79 , A61K31/343 , A61K45/06
摘要: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
摘要翻译: 提供抑制细胞色素P450酶的方法,其可用于通过防止细胞色素P450对药物或其它分子的降解来改善疾病的治疗。 提供的药物组合物可用作增效剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450酶体内降解的药物的治疗效果。
-
2.
公开(公告)号:US08673970B2
公开(公告)日:2014-03-18
申请号:US12919011
申请日:2009-02-23
申请人: Michael Eissenstat , Dehui Duan , John W. Erickson
发明人: Michael Eissenstat , Dehui Duan , John W. Erickson
CPC分类号: A61K45/06 , A61K31/34 , A61K2300/00
摘要: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.
摘要翻译: 提供了治疗病毒感染的组合物和方法。 更具体地,提供包含蛋白酶抑制剂和细胞色素p450酶抑制剂的组合的组合物。 还提供了使用组合物治疗由病毒如HIV感染引起的疾病或病症的方法。
-
公开(公告)号:US20110182854A1
公开(公告)日:2011-07-28
申请号:US13060243
申请日:2009-08-20
申请人: Michael Eissenstat , Rongjian Lu , Sang Uk Kang
发明人: Michael Eissenstat , Rongjian Lu , Sang Uk Kang
IPC分类号: A61K38/21 , C07D487/14 , C07D519/00 , A61K31/4709 , A61K31/5377 , A61K31/407 , A61K31/4725 , A61K31/4184 , A61K31/427 , A61K31/4155 , A61K31/4439 , A61K31/422 , A61K31/7056 , A61K31/7088 , A61P31/14
CPC分类号: C07D487/14 , C07K5/0804
摘要: Novel compounds that are potent inhibitors of hepatitis C virus protease are provided. Pharmaceutical compositions containing one or more of these inhibitors, methods of preparing the inhibitors and methods of using the inhibitors to treat hepatitis C and related disorders also are provided.
摘要翻译: 提供了作为丙型肝炎病毒蛋白酶的有效抑制剂的新型化合物。 还提供了含有这些抑制剂中的一种或多种的药物组合物,制备抑制剂的方法以及使用抑制剂治疗丙型肝炎和相关疾病的方法。
-
公开(公告)号:US07981929B2
公开(公告)日:2011-07-19
申请号:US12050125
申请日:2008-03-17
申请人: Michael Eissenstat
发明人: Michael Eissenstat
IPC分类号: A61K31/343 , C07D307/78 , C07D407/12
CPC分类号: C07D493/04
摘要: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
摘要翻译: 提供抗驱虫和多药耐药的逆转录病毒蛋白酶抑制剂。 还提供了包含这些化合物的药物组合物,以及使用这些化合物治疗哺乳动物HIV感染的方法。
-
公开(公告)号:US20110124578A1
公开(公告)日:2011-05-26
申请号:US12919009
申请日:2009-02-23
申请人: Michael Eissenstat , Dehui Duan , Jihye Kang
发明人: Michael Eissenstat , Dehui Duan , Jihye Kang
IPC分类号: A61K38/12
CPC分类号: C07D307/79 , C07D307/82 , C07D405/12 , C07D405/14 , C07D417/12 , C07D417/14
摘要: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that eases can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
摘要翻译: 提供抑制细胞色素P450酶的方法,其可用于通过防止细胞色素P450对药物或其它分子的降解来改善疾病的治疗。 提供了药物组合物,其可以作为增强剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450酶进行体内降解的药物的治疗效果。
-
公开(公告)号:US20090143408A1
公开(公告)日:2009-06-04
申请号:US12324507
申请日:2008-11-26
申请人: Michael EISSENSTAT , Dehui Duan , Ji-Hye Kang
发明人: Michael EISSENSTAT , Dehui Duan , Ji-Hye Kang
IPC分类号: A61K31/497 , C07D307/78 , C07D407/12 , C07D405/12 , C12N9/99 , A61K31/343 , A61K31/443
CPC分类号: C07D307/79 , A61K31/343 , A61K31/4178 , A61K31/4196 , A61K31/437 , A61K31/443 , A61K31/444 , A61K31/485 , A61K31/497 , C07D405/12 , C07D405/14 , C07D407/12 , C07D471/04 , C12N9/0077 , C12Y114/14001
摘要: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.
摘要翻译: 提供了抑制细胞色素P450 2D6酶的方法,可用于通过细胞色素P450 2D6阻止药物或其他分子的降解来改善疾病的治疗。 提供的药物组合物可用作增强剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450 2D6酶体内降解的药物的治疗效果。
-
公开(公告)号:US20070207952A1
公开(公告)日:2007-09-06
申请号:US10550715
申请日:2004-03-24
CPC分类号: C07K14/765 , A61K38/00 , A61K47/643
摘要: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.
摘要翻译: 本发明提供可与大分子如白蛋白反应的生物活性化合物以形成共价连接的络合物,其中所得的复合物在体内显示出所需的生物学活性。 更具体地,复合物是包含与连接基团和蛋白质共价结合的生物活性部分的分离的复合物。 通过将生物活性部分例如肾素抑制剂或病毒融合抑制剂肽与纯化和分离的蛋白质缀合来制备复合物。 与非共轭分子相比,复合物在血液中的寿命延长,与非共轭分子相比,延长的时间段具有生物活性。 本发明还提供了抗病毒化合物,其是病毒感染的抑制剂和/或表现出抗融合生物学特性。 特别地,本发明提供了对人体免疫缺陷病毒(HIV),呼吸道合胞病毒(RSV),人副流感病毒(HPV),麻疹病毒(MeV)和猿猴免疫缺陷病毒(SIV)等病毒具有抑制活性的化合物, 延长了治疗病毒感染的时间。
-
公开(公告)号:US08906647B2
公开(公告)日:2014-12-09
申请号:US12919008
申请日:2009-02-23
申请人: Michael Eissenstat , Dehui Duan
发明人: Michael Eissenstat , Dehui Duan
IPC分类号: C07D405/14 , C12P33/20 , G01N33/15 , C07D307/79 , C07D417/12 , C07D417/14 , C07D405/12 , C07D409/12 , C07D231/12 , C07D405/06
CPC分类号: C07D405/14 , A61K31/343 , A61K31/4155 , A61K31/443 , A61K45/06 , C07D231/12 , C07D307/79 , C07D307/81 , C07D405/06 , C07D405/12 , C07D409/12 , C07D417/12 , C07D417/14 , Y10T436/14
摘要: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
摘要翻译: 提供抑制细胞色素P450酶的方法,其可用于通过防止细胞色素P450对药物或其它分子的降解来改善疾病的治疗。 提供的药物组合物可用作增效剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450酶体内降解的药物的治疗效果。
-
公开(公告)号:US08481520B2
公开(公告)日:2013-07-09
申请号:US13287079
申请日:2011-11-01
申请人: Michael Eissenstat , Dehui Duan
发明人: Michael Eissenstat , Dehui Duan
IPC分类号: A61K31/33
CPC分类号: A61K31/343 , A61K31/33 , A61K31/4155 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/427 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K45/06 , C07D307/79 , C07D405/12 , C07D405/14 , C07D417/12 , C07D471/04 , C07D491/048 , A61K2300/00
摘要: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
摘要翻译: 提供抑制细胞色素P450酶的方法,其可用于通过防止细胞色素P450对药物或其它分子的降解来改善疾病的治疗。 提供的药物组合物可用作增效剂以改善药代动力学,增强生物利用度,并增强经细胞色素P450酶体内降解的药物的治疗效果。
-
公开(公告)号:US20120141414A1
公开(公告)日:2012-06-07
申请号:US13322120
申请日:2010-05-24
申请人: Pavel Majer , Michael Eissenstat , Rongjuan Lu
发明人: Pavel Majer , Michael Eissenstat , Rongjuan Lu
CPC分类号: A61K31/7056 , A61K31/01 , A61K31/44 , A61K38/21 , A61K45/06 , C07D471/16 , C07D487/04 , C07D513/16 , A61K2300/00
摘要: Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.
摘要翻译: 提供丙型肝炎病毒(HCV)NS3蛋白酶的抑制剂。 特别地,提供了双丙环化合物及其用于治疗HCV感染的药物组合物。 还提供了制备双丙环化合物及其药物组合物的方法,以及使用该化合物治疗HCV感染的方法。
-
-
-
-
-
-
-
-
-